Quarterly ResultMay 14, 2026, 04:14 PM
Artelo Biosciences Q1 Cash $10.27M; Equity Turns Positive
AI Summary
Artelo Biosciences reported a net loss of $2.958 million for Q1 2026, an increase from $2.372 million in Q1 2025. Despite the increased loss, the company significantly improved its financial position, with cash and cash equivalents rising to $10.273 million from $0.600 million at year-end 2025, and stockholders' equity turning positive to $6.672 million from a deficit of $1.272 million. This improvement was primarily driven by $10.033 million in net proceeds from a private placement offering in March 2026, which also included the issuance of warrants and convertible notes. The company acknowledged substantial doubt about its ability to continue as a going concern, but the recent financing provides immediate capital.
Key Highlights
- Cash and cash equivalents surged to $10.273 million as of March 31, 2026, from $0.600 million at December 31, 2025.
- Stockholders' equity turned positive to $6.672 million from a deficit of $1.272 million.
- Net loss for Q1 2026 increased to $2.958 million from $2.372 million in Q1 2025.
- Basic and diluted loss per share improved to $(4.00) from $(12.55) year-over-year.
- Net cash provided by financing activities was $10.860 million in Q1 2026.
- Raised $10.033 million net from a private placement offering in March 2026.
- Research and development expenses decreased to $773 thousand from $1.384 million year-over-year.
- General and administrative expenses increased to $1.916 million from $0.995 million year-over-year.